Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
SELECTA BIOSCIENCES INC (SELB) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics"
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
04/04/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT"
03/21/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint",
"Slide Presentation of Selecta Biosciences, Inc."
01/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease",
"Selecta Biosciences Provides Business Update and Outlook for 2023",
"January 2023 Selecta Biosciences Corporate Presentation SELB 2Selecta Biosciences Investor Presentation"
12/14/2022 8-K Quarterly results
11/28/2022 8-K Quarterly results
11/18/2022 8-K Investor presentation
Docs: "2022 PLACEHOLDER FOR SPLASH PAGE"
11/03/2022 8-K Quarterly results
08/22/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BYLAWS OF"
08/04/2022 8-K Investor presentation
Docs: "2022 PLACEHOLDER FOR SPLASH PAGE"
08/04/2022 8-K Quarterly results
Docs: "Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update"
06/30/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/18/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/13/2022 8-K Investor presentation
Docs: "2022 PLACEHOLDER FOR SPLASH PAGE"
04/07/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and between Selecta Biosciences, Inc. and SVB Securities LLC, as representative of the several underwriters named therein",
"Form of Warrant",
"Opinion of Covington & Burling LLP",
"Selecta Biosciences Announces $38.7 Million Underwritten Offering WATERTOWN, Mass., April 6, 2022 - Selecta Biosciences, Inc. , a biotechnology company focused on developing tolerogenic therapies to mitigate unwanted immune responses, today announced that it has agreed to sell 27,428,572 shares of its common stock and accompanying warrants to purchase up to 20,571,429 shares of common stock at a combined offering price of $1.41 per share and accompanying warrant. The warrants to purchase shares of common stock have an exercise price of $1.55 per share, are immediately exercisable and will expire five years from the date of issuance. All of the securities in the offering will be sold by Selecta. The gross proceeds to Selecta from the offering, before deducting underwriting discounts and com..."
04/06/2022 8-K Investor presentation
Docs: "Corporate slide presentation of Selecta Biosciences, Inc. dated April 2022"
03/22/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT"
03/10/2022 8-K Quarterly results
02/16/2022 8-K Investor presentation
Docs: "2022 PLACEHOLDER FOR SPLASH PAGE"
02/10/2022 8-K Other Events  Interactive Data
01/10/2022 8-K Other Events  Interactive Data
11/24/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Selecta Biosciences Provides Update on Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia"
11/09/2021 8-K Quarterly results
Docs: "Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update"
11/08/2021 8-K Investor presentation
Docs: "Slide Presentation of Selecta Biosciences, Inc."
10/26/2021 8-K Other Events  Interactive Data
10/25/2021 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sales Agreement, between Selecta Biosciences, Inc. and SVB Leerink LLC",
"Opinion of Covington & Burling LLP"
10/21/2021 8-K Other Events  Interactive Data
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy